Hikma Pharmaceutical | HIK - Cost Of Sales



Hikma Pharmaceutical reported $895M in Cost of Sales for its fiscal semester ending in December of 2024.


Cost Of Sales Change Date
Almirall EUR 195.09M 100.89M Jun/2025
argenx SE USD 110.75M 29.94M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Autolus Therapeutics Ltd 24.91M 6.96M Jun/2025
Bayer EUR 4.36B 1.26B Jun/2025
Fresenius EUR 4.12B 117M Jun/2025
Galapagos EUR 4.71M 9.02M Jun/2025
Genmab DKK 57M 15M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
GRIFOLS EUR 1.15B 56.19M Jun/2025
Hikma Pharmaceutical USD 895M 82M Dec/2024
Lonza CHF 2.47B 532M Dec/2024
Merck EUR 2.23B 93M Jun/2025
Orion EUR 168.1M 15.3M Jun/2025
Recordati EUR 220.03M 1.16M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sanofi EUR 2.99B 103M Jun/2025
UCB EUR 901M 50M Dec/2024